New hope for tough leukemia cases: experimental combo enters first human trial
NCT ID NCT06445907
Summary
This is a first-in-human study to check the safety of a new three-drug combination (Q702, azacitidine, and venetoclax) for adults with acute myeloid leukemia (AML) that has returned or not responded to prior treatments. The main goal is to find a safe dose and see what side effects occur. Researchers will also look for early signs that the treatment might help control the leukemia.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.